Skip to main content
NCBI home page
Journal of Virology logoLink to Journal of Virology
. 1997 Aug;71(8):6247–6252. doi: 10.1128/jvi.71.8.6247-6252.1997

Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitope.

R B Roden 1, A Armstrong 1, P Haderer 1, N D Christensen 1, N L Hubbert 1, D R Lowy 1, J T Schiller 1, R Kirnbauer 1
PMCID: PMC191893  PMID: 9223527

Abstract

We have determined that three type-specific and conformationally dependent monoclonal antibodies, H16.E70, H16.U4, and H16.V5, neutralize pseudotype human papillomavirus type 16 (HPV16) virions in vitro. H16.U4 and H16.V5 neutralized pseudotype virions derived from the German HPV16 variant 114K and the Zairian variant Z-1194 with equal efficiency. In contrast, neutralization of Z-1194 pseudotype virions by H16.E70 was two orders of magnitude weaker than neutralization of 114K pseudotype virions. This difference correlated with enzyme-linked immunosorbent assay reactivity of H16.E70 to L1 virus-like particles of the two variants. A substitution at residue 282 of L1 was responsible for this differential reactivity, suggesting that this residue constitutes part of the H16.E70 epitope.

Full Text

The Full Text of this article is available as a PDF (234.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baker T. S., Newcomb W. W., Olson N. H., Cowsert L. M., Olson C., Brown J. C. Structures of bovine and human papillomaviruses. Analysis by cryoelectron microscopy and three-dimensional image reconstruction. Biophys J. 1991 Dec;60(6):1445–1456. doi: 10.1016/S0006-3495(91)82181-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bosch F. X., Manos M. M., Muñoz N., Sherman M., Jansen A. M., Peto J., Schiffman M. H., Moreno V., Kurman R., Shah K. V. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst. 1995 Jun 7;87(11):796–802. doi: 10.1093/jnci/87.11.796. [DOI] [PubMed] [Google Scholar]
  3. Breitburd F., Kirnbauer R., Hubbert N. L., Nonnenmacher B., Trin-Dinh-Desmarquet C., Orth G., Schiller J. T., Lowy D. R. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol. 1995 Jun;69(6):3959–3963. doi: 10.1128/jvi.69.6.3959-3963.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Cheng G., Icenogle J. P., Kirnbauer R., Hubbert N. L., St Louis M. E., Han C., Svare E. I., Kjaer S. K., Lowy D. R., Schiller J. T. Divergent human papillomavirus type 16 variants are serologically cross-reactive. J Infect Dis. 1995 Dec;172(6):1584–1587. doi: 10.1093/infdis/172.6.1584. [DOI] [PubMed] [Google Scholar]
  5. Christensen N. D., Dillner J., Eklund C., Carter J. J., Wipf G. C., Reed C. A., Cladel N. M., Galloway D. A. Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies. Virology. 1996 Sep 1;223(1):174–184. doi: 10.1006/viro.1996.0466. [DOI] [PubMed] [Google Scholar]
  6. Christensen N. D., Kirnbauer R., Schiller J. T., Ghim S. J., Schlegel R., Jenson A. B., Kreider J. W. Human papillomavirus types 6 and 11 have antigenically distinct strongly immunogenic conformationally dependent neutralizing epitopes. Virology. 1994 Nov 15;205(1):329–335. doi: 10.1006/viro.1994.1649. [DOI] [PubMed] [Google Scholar]
  7. Christensen N. D., Kreider J. W. Antibody-mediated neutralization in vivo of infectious papillomaviruses. J Virol. 1990 Jul;64(7):3151–3156. doi: 10.1128/jvi.64.7.3151-3156.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Christensen N. D., Kreider J. W., Cladel N. M., Patrick S. D., Welsh P. A. Monoclonal antibody-mediated neutralization of infectious human papillomavirus type 11. J Virol. 1990 Nov;64(11):5678–5681. doi: 10.1128/jvi.64.11.5678-5681.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Christensen N. D., Kreider J. W. Monoclonal antibody neutralization of BPV-1. Virus Res. 1993 May;28(2):195–202. doi: 10.1016/0168-1702(93)90136-b. [DOI] [PubMed] [Google Scholar]
  10. Christensen N. D., Kreider J. W. Neutralization of CRPV infectivity by monoclonal antibodies that identify conformational epitopes on intact virions. Virus Res. 1991 Nov;21(3):169–179. doi: 10.1016/0168-1702(91)90031-p. [DOI] [PubMed] [Google Scholar]
  11. Doorbar J., Gallimore P. H. Identification of proteins encoded by the L1 and L2 open reading frames of human papillomavirus 1a. J Virol. 1987 Sep;61(9):2793–2799. doi: 10.1128/jvi.61.9.2793-2799.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Hagensee M. E., Olson N. H., Baker T. S., Galloway D. A. Three-dimensional structure of vaccinia virus-produced human papillomavirus type 1 capsids. J Virol. 1994 Jul;68(7):4503–4505. doi: 10.1128/jvi.68.7.4503-4505.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Icenogle J. P., Clancy K. A., Lin S. Y. Sequence variation in the capsid protein genes of human papillomavirus type 16 and type 31. Virology. 1995 Dec 20;214(2):664–669. doi: 10.1006/viro.1995.0082. [DOI] [PubMed] [Google Scholar]
  14. Kirnbauer R., Booy F., Cheng N., Lowy D. R., Schiller J. T. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci U S A. 1992 Dec 15;89(24):12180–12184. doi: 10.1073/pnas.89.24.12180. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Kirnbauer R., Chandrachud L. M., O'Neil B. W., Wagner E. R., Grindlay G. J., Armstrong A., McGarvie G. M., Schiller J. T., Lowy D. R., Campo M. S. Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology. 1996 May 1;219(1):37–44. doi: 10.1006/viro.1996.0220. [DOI] [PubMed] [Google Scholar]
  16. Kirnbauer R., Taub J., Greenstone H., Roden R., Dürst M., Gissmann L., Lowy D. R., Schiller J. T. Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J Virol. 1993 Dec;67(12):6929–6936. doi: 10.1128/jvi.67.12.6929-6936.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Liljeström P., Garoff H. A new generation of animal cell expression vectors based on the Semliki Forest virus replicon. Biotechnology (N Y) 1991 Dec;9(12):1356–1361. doi: 10.1038/nbt1291-1356. [DOI] [PubMed] [Google Scholar]
  18. Ludmerer S. W., Benincasa D., Mark G. E., 3rd Two amino acid residues confer type specificity to a neutralizing, conformationally dependent epitope on human papillomavirus type 11. J Virol. 1996 Jul;70(7):4791–4794. doi: 10.1128/jvi.70.7.4791-4794.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. McLean C. S., Churcher M. J., Meinke J., Smith G. L., Higgins G., Stanley M., Minson A. C. Production and characterisation of a monoclonal antibody to human papillomavirus type 16 using recombinant vaccinia virus. J Clin Pathol. 1990 Jun;43(6):488–492. doi: 10.1136/jcp.43.6.488. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Müller M., Gissmann L., Cristiano R. J., Sun X. Y., Frazer I. H., Jenson A. B., Alonso A., Zentgraf H., Zhou J. Papillomavirus capsid binding and uptake by cells from different tissues and species. J Virol. 1995 Feb;69(2):948–954. doi: 10.1128/jvi.69.2.948-954.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Pisani P., Parkin D. M., Ferlay J. Estimates of the worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden. Int J Cancer. 1993 Dec 2;55(6):891–903. doi: 10.1002/ijc.2910550604. [DOI] [PubMed] [Google Scholar]
  22. Robbins J. B., Schneerson R., Szu S. C. Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. J Infect Dis. 1995 Jun;171(6):1387–1398. doi: 10.1093/infdis/171.6.1387. [DOI] [PubMed] [Google Scholar]
  23. Roden R. B., Greenstone H. L., Kirnbauer R., Booy F. P., Jessie J., Lowy D. R., Schiller J. T. In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype. J Virol. 1996 Sep;70(9):5875–5883. doi: 10.1128/jvi.70.9.5875-5883.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Roden R. B., Hubbert N. L., Kirnbauer R., Breitburd F., Lowy D. R., Schiller J. T. Papillomavirus L1 capsids agglutinate mouse erythrocytes through a proteinaceous receptor. J Virol. 1995 Aug;69(8):5147–5151. doi: 10.1128/jvi.69.8.5147-5151.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Roden R. B., Hubbert N. L., Kirnbauer R., Christensen N. D., Lowy D. R., Schiller J. T. Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition. J Virol. 1996 May;70(5):3298–3301. doi: 10.1128/jvi.70.5.3298-3301.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Roden R. B., Kirnbauer R., Jenson A. B., Lowy D. R., Schiller J. T. Interaction of papillomaviruses with the cell surface. J Virol. 1994 Nov;68(11):7260–7266. doi: 10.1128/jvi.68.11.7260-7266.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Roden R. B., Weissinger E. M., Henderson D. W., Booy F., Kirnbauer R., Mushinski J. F., Lowy D. R., Schiller J. T. Neutralization of bovine papillomavirus by antibodies to L1 and L2 capsid proteins. J Virol. 1994 Nov;68(11):7570–7574. doi: 10.1128/jvi.68.11.7570-7574.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Rose R. C., Bonnez W., Da Rin C., McCance D. J., Reichman R. C. Serological differentiation of human papillomavirus types 11, 16 and 18 using recombinant virus-like particles. J Gen Virol. 1994 Sep;75(Pt 9):2445–2449. doi: 10.1099/0022-1317-75-9-2445. [DOI] [PubMed] [Google Scholar]
  29. Schiller J. T., Okun M. M. Papillomavirus vaccines: current status and future prospects. Adv Dermatol. 1996;11:355–381. [PubMed] [Google Scholar]
  30. Suzich J. A., Ghim S. J., Palmer-Hill F. J., White W. I., Tamura J. K., Bell J. A., Newsome J. A., Jenson A. B., Schlegel R. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11553–11557. doi: 10.1073/pnas.92.25.11553. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Volpers C., Unckell F., Schirmacher P., Streeck R. E., Sapp M. Binding and internalization of human papillomavirus type 33 virus-like particles by eukaryotic cells. J Virol. 1995 Jun;69(6):3258–3264. doi: 10.1128/jvi.69.6.3258-3264.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Yamada T., Wheeler C. M., Halpern A. L., Stewart A. C., Hildesheim A., Jenison S. A. Human papillomavirus type 16 variant lineages in United States populations characterized by nucleotide sequence analysis of the E6, L2, and L1 coding segments. J Virol. 1995 Dec;69(12):7743–7753. doi: 10.1128/jvi.69.12.7743-7753.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. zur Hausen H. Human papillomaviruses in the pathogenesis of anogenital cancer. Virology. 1991 Sep;184(1):9–13. doi: 10.1016/0042-6822(91)90816-t. [DOI] [PubMed] [Google Scholar]
  34. zur Hausen H. Molecular pathogenesis of cancer of the cervix and its causation by specific human papillomavirus types. Curr Top Microbiol Immunol. 1994;186:131–156. doi: 10.1007/978-3-642-78487-3_8. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES